STRO vs. INMB, CADL, ADVM, CHRS, OPT, CMPX, CRDF, ABOS, PSTX, and IPSC
Should you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include INmune Bio (INMB), Candel Therapeutics (CADL), Adverum Biotechnologies (ADVM), Coherus BioSciences (CHRS), Opthea (OPT), Compass Therapeutics (CMPX), Cardiff Oncology (CRDF), Acumen Pharmaceuticals (ABOS), Poseida Therapeutics (PSTX), and Century Therapeutics (IPSC). These companies are all part of the "biological products, except diagnostic" industry.
INmune Bio (NASDAQ:INMB) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends.
INmune Bio presently has a consensus price target of $16.00, indicating a potential upside of 49.53%. Sutro Biopharma has a consensus price target of $12.50, indicating a potential upside of 184.74%. Given INmune Bio's higher probable upside, analysts clearly believe Sutro Biopharma is more favorable than INmune Bio.
12.7% of INmune Bio shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 36.1% of INmune Bio shares are held by company insiders. Comparatively, 6.9% of Sutro Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
INmune Bio has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.
INmune Bio has higher earnings, but lower revenue than Sutro Biopharma. INmune Bio is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.
INmune Bio received 17 more outperform votes than Sutro Biopharma when rated by MarketBeat users. Likewise, 75.69% of users gave INmune Bio an outperform vote while only 64.17% of users gave Sutro Biopharma an outperform vote.
Sutro Biopharma has a net margin of -69.47% compared to Sutro Biopharma's net margin of -19,360.00%. Sutro Biopharma's return on equity of -64.11% beat INmune Bio's return on equity.
In the previous week, Sutro Biopharma had 3 more articles in the media than INmune Bio. MarketBeat recorded 5 mentions for Sutro Biopharma and 2 mentions for INmune Bio. Sutro Biopharma's average media sentiment score of 0.63 beat INmune Bio's score of 0.14 indicating that INmune Bio is being referred to more favorably in the media.
Summary
INmune Bio beats Sutro Biopharma on 9 of the 17 factors compared between the two stocks.
Get Sutro Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sutro Biopharma Competitors List
Related Companies and Tools
